<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629925</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308C303</org_study_id>
    <nct_id>NCT03629925</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Recurrent Squamous NSCLC</brief_title>
  <official_title>A Randomized, Double-blind, Phase III Study of Gemcitabine +Carboplatin/Cisplatin Chemotherapy With or Without Sintilimab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (Orient-12)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous
      NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The anti-tumor activity of anti-PD-1 therapy in previously untreated Chinese squamous NSCLC
      patients will be investigated in this clinical trial. Sintilimab is expected to increase the
      PFS from 5.5 months to 7.9 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(progression free survival)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of the first documented tumor progression per RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>OS was defined as the time between the date of randomization and the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR(objective response rate)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment(per RECIST v1.1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Squamous NSCLC</condition>
  <arm_group>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sintilimab Injection (Dosage form:10ml:100mg; Frequency: 200mg Q3W; Duration: until first documented tumor progression per RECIST v1.1 criteria) Sintilimab 200mg + gemcitabine plus platinum for 4 cycles followed by Sintilimab 200mg Q3W until first documented tumor progression per RECIST v1.1 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + gemcitabine plus platinum Q3W for 4 cycles followed by placebo (Conditional crossover to sintilimab 200mg Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>10 mL:100 mg，200mg，Q3W, day1, I.V.</description>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/m^2,D1D8/Q3W;first 4 cycles.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 mL:100 mg，200mg，Q3W, day1, I.V.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum</intervention_name>
    <description>Q3W, day1, I.V.; first 4 cycles.</description>
    <arm_group_label>Placebo+gemcitabine plus platinum</arm_group_label>
    <arm_group_label>Sintilimab+ gemcitabine plus platinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent before any trial-related processes;

          2. Age ≥ 18 years and &lt;75 years;

          3. Life expectancy exceeds 3 months;

          4. The investigator confirms at least one measurable lesion according to RECIST 1.1.

             A measurable lesion located in the field of previous radiation therapy or after local
             treatment may be selected as a target lesion if progression is confirmed;

          5. Has a histologically or cytologically confirmed stage IIIB/IIIC (American Joint
             Committee on Cancer [AJCC] 8th edition) NSCLC that is unresectable and not fit for
             radical concurrent chemoradiotherapy, or metastatic / recurrent squamous NSCLC;

          6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

          7. Has not received any systematic anti-tumor treatment for advanced disease. The patient
             may have received adjuvant chemotherapy as long as the disease progresses at least 6
             months after the last dose of chemotherapy;

          8. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×109 /L,
             platelet count ≥100 ×109 /L, hemoglobin ≥9g/dL (no blood transfusion within 7 days);

          9. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper
             limit (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
             levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times ULN for patients with hepatic
             metastasis;

         10. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or creatinine
             clearance ≥ 50 ml / min (Cockcroft-Gault formula);

         11. Coagulation function is adequate, defined as international normalized ratio (INR) or
             prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN). If the subject is
             receiving anticoagulant therapy, the INR/PT level is required to be within the
             therapeutic scope;

         12. Urine or serum pregnancy test should be negative for female subjects of childbearing
             age. If the urine pregnancy test results are positive or cannot be confirmed, a blood
             pregnancy test is required;

         13. Male and female patients with childbearing potential are required to use
             high-efficiency contraception until at least 180 days after stopping the trial
             treatment;

        Exclusion Criteria:

          1. Non-squamous cell-dominated NSCLC. If small cell types are present, the subject is not
             eligible for inclusion;

          2. Patients with known EGFR-sensitive mutations or ALK rearrangements;

          3. Currently participating in or has participated in other interventional clinical study
             within 4 weeks;

          4. Has previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2
             drugs or any other stimulatory or inhibitory agents of T cell receptors (eg CTLA-4,
             OX-40, CD137);

          5. Has received a traditional Chinese medicine with anti-tumor effect, or any
             immunomodulatory drug (thymosin, interferon, interleukin) within 2 weeks, or received
             major surgery within 3 weeks;

          6. Clinical active diverticulitis, abdominal abscess, gastrointestinal obstruction and
             peritoneal metastasis;

          7. Has received a organ or blood system transplantation;

          8. Clinically uncontrollable pleural effusion/peritoneal effusion;

          9. Known to have severe allergic reactions (≥3 grade) to Sintilimab, gemcitabine,
             cisplatin or carboplatin;

         10. Active autoimmune diseases requiring systemic treatment (eg, using a disease-modifying
             drug, corticosteroid or immunosuppressant) within 2 years prior to the first study
             treatment. Hormone replacement (such as thyroxine, insulin, or physiological
             corticosteroids for adrenal or pituitary insufficiency) are not considered as systemic
             treatments;

         11. Diagnosed of immunodeficiency or has received systemic steroid therapy or any other
             form of immunosuppressive therapy within 7 days prior to the first dose of study
             drugs. Physiological doses of corticosteroids (≤10 mg/day of prednisone or equivalent)
             are permitted;

         12. Has not fully recovered from the toxicity and/or complications caused by any
             intervention before starting treatment (ie, CTCAE v4.03 Grade ≤1 or recovering to
             baseline, except for fatigue or alopecia);

         13. Other malignancies diagnosed within 5 years prior to the first dose of study drugs,
             with the exception of radically resected cutaneous basal cell carcinoma, cutaneous
             squamous cell carcinoma, and carcinoma in situ;

         14. Active central nervous system (CNS) metastasis and/or cancerous meningitis. Patients
             with treated brain metastases who were clinically stable for at least 2 weeks and have
             no new or advanced brain metastases may be enrolled. Patients with known untreated,
             asymptomatic brain metastases can be enrolled provided cerebral imaging assessment be
             regularly performed.

         15. History of pneumonitis requiring steroid therapy or the presence of interstitial lung
             disease within 1 year prior to the first dose of study drugs;

         16. Presence of active infections that require systemic treatment;

         17. Any known mental illness or substance abuse that may have an impact on compliance with
             the test requirements;

         18. History of human immunodeficiency virus (HIV) infection (ie, HIV 1/2 antibody
             positive).

         19. Untreated active hepatitis B;

         20. Active HCV infection (HCV antibody positive and HCV-RNA levels above the lower limit
             of detection);

         21. Vaccination with live attenuated vaccines within 30 days prior to first dose of study
             drug; Note: Inactivated virus vaccines for seasonal influenza, injectable drugs are
             permitted; however, live attenuated influenza vaccines (such as FluMist®) are not
             allowed;

         22. Any illness or disease evidence, treatment or laboratory abnormalities that may
             interfere with the subject's full participation in the study, or any condition that,
             in the investigator opinion, is not in the best interest of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

